Modern oncological treatment has rendered testicular cancer (TC) a curative malignant disease but there is a risk of decreasing survival and reduced health-related quality of life (HR-QoL) related to long-term adverse health outcomes (AHOs).
To provide an overview on AHOs after oncological treatment of TC.
Summary of published studies and previous reviews.
Relative survival rates decrease among TC survivors 25 years after diagnosis, mainly due to treatment-related second cancer and/or cardiovascular disease, the latter mediated by components of the metabolic syndrome. With increasing age cisplatin-induced ototoxicity becomes a clinical problem in patients, whereas reported peripheral neurotoxicity only exceptionally achieves major clinical relevance. Anxiety but not depression represents the dominating psychological problem. In most patients HR-QoL is good, but working ability may be reduced by very intensive treatment.
Awareness of long-term AHOs among TC survivors and health professionals can contribute to reduce long-term morbidity and mortality and to improve QoL by initiating early preventive and therapeutic measures. Radiotherapy should be avoided as much as possible during risk-adapted treatment of TC. Existing data indicate premature aging among strongly treated TC survivors but larger studies and longer follow-up in longitudinal studies are required to confirm these preliminary observations.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, American Society of Clinical Oncology, - (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 32:1840–1850 CrossRefPubMedPubMedCentral
Cappuccio F, Rossetti S, Cavaliere C, Iovane G, Taibi R, D’Aniello C et al (2018) Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review. Eur Rev Med Pharmacol Sci 22:645–661 PubMed
Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM et al (2018) Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: Application of the Framingham Risk Score. Clin Genitourin Cancer 4:e761–e769 CrossRef
Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD (2018) Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol 31:1–9
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967 CrossRefPubMed
Smith AB, Rutherford C, Butow P, Olver I, Luckett T, Grimison P et al (2017) A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psychooncology. https://doi.org/10.1002/pon.4596 (Epub ahead of print) CrossRefPubMedPubMedCentral
Sprauten M, Haugnes HS, Brydøy M et al (2015) Increasing prevalence of chronic fatigue in 812 testicualr cancer survivors: A longitudinal study. Ann Oncol 10:2133–2140 CrossRef
- Late adverse outcomes after treatment of testicular cancer
Professor em. S. D. Fosså
A. A. Dahl
- Springer Medizin
Print ISSN: 0947-8965
Elektronische ISSN: 1433-0415
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II